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ABSTRACT 
Purpose: PET/CT with F-18-Fluorodeoxyglucose (FDG) images of patients suffering 
from metastatic melanoma have been analysed using fractal and multifractal analysis 
to assess the impact of monoclonal antibody ipilimumab treatment with respect to 
therapy outcome. 
Methods: 31 cases of patients suffering from metastatic melanoma have been 
scanned before and after treatment. We calculated the fractal and multifractal 
dimensions using the boxcounting method on the digitalised PET/CT images prior and 
after treatment to assess the therapeutic outcome. We modelled the spreading of 
malignant cells in the body via kinetic Monte Carlo simulations to address the 
dynamical evolution of the metastatic process and to predict the spatial distribution of 
malignant lesions. 
Results:. Our analysis shows that the fractal dimensions which describe the tracer 
dispersion in the body decrease consistently with the deterioration of the patient’s 
therapeutic outcome condition. In 20 out-of 24 cases the fractal analysis results 
match those of the medical records, while 7 cases are considered as special cases 
because the patients have non-tumour related medical conditions or side effects 
which affect the results. The decrease in the fractal dimensions with the deterioration 
of the patient conditions (in terms of disease progression) are attributed to the hier-
archical localisation of the tracer which accumulates in the affected lesions and does 
not spread homogeneously throughout the body. Fractality emerges as a result of 
the migration patterns which the malignant cells follow for propagating within the 
body (circulatory system, lymphatic system). Analysis of the multifractal spectrum 
complements and supports the results of the fractal analysis. In the kinetic Monte 
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Carlo modelling of the metastatic process a small number of malignant cells diffuse 
throughout a fractal medium representing the blood circulatory network. Along their 
way the malignant cells engender random metastases (colonies) with a small proba-
bility and, as a result, fractal spatial distributions of the metastases are formed simi-
lar to the ones observed in the PET/CT images. 
Conclusions: We show that the Monte Carlo generated spatial distribution of 
metastases changes with time approaching values close to the ones recorded in the 
metastatic patients. Thus, we propose that fractal and multifractal analysis has 
potential application in the quantification of the evaluation of PET/CT images to 
monitor the disease evolution as well as the response to different medical treatments. 
 
INTRODUCTION 
 
Many constituent networks of the human body present complicated geometric 
structures which derive from their functional needs, i.e. the geometry of the network 
serves its functionality. Common examples are: a) the circulatory system which is 
responsible for the efficient distribution of blood in the body, b) the respiratory system 
which coordinates the transport of oxygen in the body and the collection and release 
of carbon dioxide and c) the nervous system which controls the dynamic 
transmission of information via electrical signals in the brain and throughout the body 
[1]. These three major systems are complex structures with branching and sub-
branching down in many hierarchical orders. Branching is considered as a very 
efficient and energy saving architecture to transfer matter (or information) from a 
central source (organ) to a large number of destinations. Because of branching the 
body systems are self-similar in many orders of magnitude and exhibit fractal 
scaling. 
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In particular, the blood circulatory system distributes the blood in the whole body 
starting from an organ of large size and reaching individual cells. To achieve this, the 
distribution network starts from a large artery leaving the heart and branches out in 
many levels. At each level, the number of branches increases while their diameter 
decreases in order to reach and feed all cells. This is a mathematical property of 
fractals in 3D which are constructed as space filling objects [2]. 
 There has been a large number of attempts to quantify the value of the fractal 
dimensions of the cardiovascular system. Already in 1977, Mandelbrot predicted that 
the fractal dimension of an arterial tree should be smaller than 3 and he coined the 
value 2.7 as plausible in refs.[2] [3]. Huang et al. measured experimentally a value 
df=2.71 for pulmonary arteries and df=2.69 for pulmonary veins [4].  Helmberger et 
al reported fractal dimensions of the lung vessels in pulmonary hypertension patients 
as df = 2.34, with df increasing to the value 2.37 for patients without pulmonary 
hypertension [5].  Gil-García et al, showed experimentally that the arterial pattern of 
the dog kidneys has fractal dimension ~2.7  [6]. 
The blood circulatory system often serves as a means of transportation for malignant 
cells to migrate through the body. As stem cancer cells migrate, they colonize distant 
areas producing metastases, which are the most frequent causes of death for 
patients with cancer. The molecular mechanisms of metastasis are still not well 
understood due to their biological complexity [7], but the   migration through the 
blood circulatory system seems plausible since all body cells come in direct contact 
and exchange with blood. With this scenario the pattern of migration and colonization 
of malignant cells should be directly linked with the structure of the distributing blood 
network. It is then reasonable to search for fractality in the distribution of metastases 
in the human body, since the transportation network distributing the cancer cells is 
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fractal. In many cases the evolution of cancer (melanoma in this case) can take a 
long time and it is a dynamical process. The final distribution is achieved only at the 
latest stages, while fractality changes during the various stages of the disease, as 
the spatial distribution of metastatic structures expands in the body. 
One molecular imaging technique for the detection of primary tumours and 
metastases is Positron Emission Tomography (PET) using the radioactive biomarker 
F-18-Deoxyglucose (FDG). This technique allows the detection of viable tumour 
tissue and is used for staging and therapy monitoring of melanoma patients since 
several years [8][9][23][24][25]. In particular, the use of hybrid systems, like PET/CT 
and PET/MRI allows a better anatomic allocation of the PET findings and leads to an 
improvement of both diagnosis and treatment planning [10]. 
Metastatic melanoma has a poor diagnosis with a median overall survival of less that 
one year until recently [11]. The conventional treatment consisted in chemotherapy, 
radiotherapy, high-dose interleukin-2 and best supportive care. An improvement of 
the overall survival was achieved after the discovery of ipilimumab [22] [26]. 
Ipilimumab is a fully human, recombinant monoclonal antibody that activates the 
immune system by targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). 
CTLA-4 is a type 1 transmembrane glycoprotein whose expression is primarily 
restricted to T cells [12]. It is a key negative regulator of T lymphocyte activation via 
antagonism of CD28-mediated co-stimulation. Melanoma, and tumours in general, 
can take advantage of this inhibitory mechanism used by the immune system to 
reduce T cell response. Therefore, the use of blocking antibodies against this 
inhibitory checkpoint, like ipilimumab, can enhance anti-tumour response. 
Bearing these in mind, it is reasonable to use fractal and multifractal analysis as a 
quantification procedure for the evaluation of FDG images to monitor the disease 
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evolution as well as the patient’s response to different medical treatments. In the 
current study we demonstrate the use of fractal/multifractal analysis in detecting the 
response of 31 melanoma patients to treatment with ipilimumab monoclonal 
antibody, as will be explained in the sequel. 
In the next section we describe the properties of the patients group and the fractal 
and multifractal methods used in the analysis of the spatial distribution of the 
metastatic lesions. In section 4 we present the main results of our study before and 
after treatment with the monoclonal antibody. Except from the results of the core 
group of patients we also present some specific cases which have non-tumor related 
findings. Also we present a minimal Kinetic Monte Carlo model which involves 
propagation of malignant cells through a fractal network causing occasional 
metastases and we compare the numerical results to those of the analysis of the 
PET/CT images. Finally, we recapitulate our main results and discuss open 
problems. 
3. MATERIALS AND METHODS 
3. 1 Patients 
The study involved 31 patients (P1, P2, …, P31) who suffered from metastatic 
melanoma at various stages of the disease. Each patient was scanned once before 
treatment (Study-I, baseline scan) and in follow-up, during and after treatment with 
the monoclonal antibody ipilimumab. Follow-up scans were performed after two 
cycles of ipilimumab treatment (Study-II, first follow-up scan), and at the end of the 
four-cycle treatment (Study-III, second follow-up scan). Due to the tendency of 
melanoma to produce metastases throughout the body, whole-body scans were 
performed in all three studies of each patient. 
Patients gave written informed consent to participate in the study and to have their 
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medical records released. The study was approved by the Ethical Committee of the 
University of Heidelberg and the Federal Agency of Radiation Protection. 
3.2 Data acquisition 
Whole-body PET/CT studies were performed from the skull to the toes with an image 
duration of two minutes per bed position for the emission scans. A dedicated PET/CT 
system (Biograph mCT, S128, Siemens Co., Erlangen, Germany) with an axial field 
of view of 21.6 cm with TruePoint and TrueV, operated in a three-dimensional mode 
was used. A low-dose attenuation CT (120kV, 30 mA) was used for attenuation 
correction of the PET data and for image fusion. All PET images were attenuation-
corrected and an image matrix of 400 x 400 pixels was used for iterative image 
reconstruction. Iterative image reconstruction was based on the Ordered Subset 
Expectation Maximization Algorithm (OSEM) with six iterations and twelve subsets. 
The reconstructed images were converted to Standardized Uptake Value (SUV) 
images based on the formula: 
𝑆𝑈𝑉 = 𝑡𝑖𝑠𝑠𝑢𝑒 𝑐𝑜𝑛𝑠𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝐵! 𝑔𝑖𝑛𝑗𝑒𝑐𝑡𝑒𝑑 𝑑𝑜𝑠𝑒 𝐵! 𝑏𝑜𝑑𝑦  𝑤𝑒𝑖𝑔ℎ𝑡 𝑔        3.1  
SUVs were calculated for the lesions with the most intense tracer uptake and a 
functional tumor diameter larger than 1 cm, which was considered to be malignant. 
These lesions were re-evaluated in the follow-up studies. 
As was explained in section 3.1, for each patient Pi , i=1, …, 31,  three  whole-body 
scans were obtained: the baseline scans and the two follow-up scans. Each one of 
these three sequences comprises about 400 images. The specifications of the PET 
images are given in Table 1. 
It must be noted here that F-18-Deoxyglucose(FDG) also concentrates 
physiologically in several healthy organs where metabolic activity takes place. These 
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organs are the heart, the brain, the liver, the urinary tract (due to tracer extraction) 
etc. Because it is not possible to systematically differentiate between non-malignant 
enhanced FDG activity (e.g. in inflammatory lesions) and abnormal activity in the 
tumorous lesions, a systematic error is introduced in the calculations of the fractal 
dimensions. This systematic error will be discussed further in the results section. 
3.3. Data analysis 
Evaluation of the PET/CT data was performed using a dedicated software (Pmod 
Technologies, Zuerich, Switzerland and Aycan Digitalsysteme, Würzburg, Germany). 
Visual analysis was performed by two nuclear medicine physicians evaluating the 
hypermetabolic areas on transaxial, coronal, and sagittal images which were 
considered to be malignant. The semi-quantitative (SUV) evaluation was based on 
irregular Volumes-of-Interest (VOIs), drawn with an isocontour based on a 
pseudosnake algorithm, placed over foci of increased 18F-FDG uptake in the 
selected areas. In general terms, foci presenting a significantly enhanced 18F-FDG 
uptake were considered indicative for melanoma after comparison with the 
morphology obtained by the CT images. Patient history was studied thoroughly in 
order to exclude possible causes of non-specific tracer accumulation and therefore 
minimize false-positive findings. Tumour response was based on the EORTC criteria. 
Details about the data evaluation have been previously published [8]. 
3.4 Fractal and Multifractal analysis 
As discussed in the Introduction, melanoma is a fast evolving tumour which expands 
forming numerous lesions throughout the body. To quantify the spatial extension of 
the metastases, we use fractal analysis which takes into account only the positions 
of the lesions, while multifractal analysis accounts also for the size of the metastases 
in each affected area. The advantage of using fractal analysis to address this 
9	
problem is that there exist a number of growth models / schemes which give rise to 
fractal structures. Depending on the outcome fractal dimension we can then point to 
the appropriate mechanisms, responsible for the spreading of the tumours. 
From the many measures which are proposed for calculating fractality of the 
spreading, we use here the most classic one, the box-counting dimensions. This 
measure has the advantage of being easy to implement and it gives directly a means 
of differentiating between homogeneous and hierarchical arrangement of the lesions. 
To implement the box-counting method, we divide the 3D PET/CT image of the 
human body in cubic boxes (3D pixels-voxels) of linear size s. The voxel linear size 
was chosen considering the pixel size and the image thickness (Table 1). According 
to the images specifications the pixel size is approximately 2mm X 2mm and the 
image thickness is 4mm. To be consistent in the three directions we construct cubic 
boxes with minimum length smin = 4mm up to smax = 200 mm.    
For each value of box size s we calculate the number of cubic boxes N(s) which 
contain tumour cells (primary or metastatic). The presence of tumour cells in a given 
position is recorded by the presence of the tracer. By plotting N(s) as a function of s 
we extract the fractal dimension df fitting the data to the following formula: 
                  𝑁 𝑠 = 𝐶𝑠!!!                              3.2  
where C is a constant, determined also by the above fit. Alternatively, we can plot 
N(s) as a function of s in a double logarithmic scale and the fractal dimension is 
calculated as the slope of this curve. 
In these calculations a systematic error arises because the tracer accumulates not 
only in malignant regions but also in some healthy organs as well as in non-tumor 
related findings (e.g. inflammatory lesions). This error tends to increase the fractal 
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dimension towards the value 3, since the organs contribute substantial 
accumulations of tracer in 3D volumes.   
While fractal analysis uses only the presence of the tracer in the particular lesion, 
multifractal analysis takes also into account the concentration of the tracer which is 
accounted for by the intensity pi of the color in each voxel i. In this case we use the 
smallest box sizes available, because the multifractal spectrum requires the finest 
details of the spatial structure. For the present scans the smallest box size available 
is (4mm x 4mm x 4mm). The generalized dimensions Dq (or multifractal spectrum) 
are calculated as follows: 
𝐷! = 𝑙𝑖𝑚!→! 1𝑞 − 1 1𝑙𝑛𝑠 𝑝!!!!!!              3.3  
where q is the dimension index which takes real values (-∞,..., 0, …, +∞), s = 4mm, 
the index i runs over all boxes and N is the total number of boxes of size (4mm x 
4mm x 4mm) covering the body. Note that the negative values of q highlight the 
smallest values of pi (rare events), while the larger positive values of pi are 
accentuated by the positive values of q. 
4. RESULTS 
4.1 Typical Patients 
For each patient we calculated the box-counting dimensions according to formula 
3.2, before medical treatment (Study-I, baseline scan), after two cycles of 
ipilimumab treatment (Study-II, first follow-up scan), and at the end of the four-cycle 
treatment (Study-III, second follow-up scan).   
The general analysis and comparison between the fractal dimensions before and 
after treatment shows that the tracer has the tendency to spread in higher 
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dimensionality in healthy subjects and also when the treatment is successful.  Typical 
healthy subjects demonstrate fractal dimensions (in physiological distribution of the 
tracer) around 2.75. The tracer tends to spread almost homogeneously throughout 
the body in healthy subjects, or concentrates in organs where biochemical activity 
takes place. In these cases the spreading shows fractal dimension almost equal 
(very close) to 3. Instead, when lesions are spread throughout the body the fractal 
dimensions decrease because the tracer tends to concentrate in a subspace of lower 
dimensions, where the metastases are active. Using the patients’ medical records as 
reference, we see that when the treatment with ipilimumab is successful the fractal 
dimension increases, when the patient's condition is stable df does not change 
drastically, and when the patient's condition deteriorates df   decreases further. 
A representative plot for patient P3, is shown in Fig. 4.1. With the red line we 
represent the analysis of Study-I, when the metastatic melanoma was diagnosed, 
with the blue line is the analysis after two cycles of ipilimumab treatment (Study-II) 
and with the green line the analysis after four cycles of treatment (Study-III). As 
indicated by the medical records, the patient at the baseline Study-I showed low 
fractal dimensions df(I)=2.46 (metastatic invasion). After two cycles we have an 
improvement of the patient’s condition and df(II) increased to 2.64, and after four 
cycles df(III) did not change substantially, showing a stable phase of the disease. In 
the same figure, the line corresponding to the analysis of a healthy subject is plotted, 
for comparison. 
The results of the multifractal spectrum verify further the fractal analysis. For the 
same patient the generalized dimensions are presented in Fig. 4.2. Again, the red 
line which corresponds to the initial diagnosis of the disease (Study-I) is lower than 
all other lines. The blue line which records the analysis after two cycles of medical 
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treatment (Study-II) and the green line, after four medical treatments (Study-III) are 
at the same level higher than the baseline spectrum. This indicates improvement in 
the patient conditions and elimination of malignant lesions. The black line which 
denotes the multifractal spectrum of a healthy subject is at the same level as the 
Studies II and III. 
Another representative plot from patient P12, whose condition according the medical 
records deteriorates during therapy, is shown in Fig 4.3. In this case, the df value 
drops successively among the different studies. On Study-I the fractal dimension 
showed the highest value df(I)=2.63. Αs the disease progressed a decrease in df 
values is shown with df(IΙ)=2.59  and df(IΙΙ)=2.56 respectively. The above confirms 
the hypothesis that in the presence of developing malignant lesions the tracer tends 
to accumulate in them, showing hierarchical expansion of low dimensionality. Figure 
4.4 presents the multifractal spectrum for the same patient. The curve shapes 
corroborate the results of the fractal analysis showing a similar decreasing tendency. 
The results for all patients are recorded on Table 2. In the 1st column the patient 
index is given, as P1, P2, … P31. In the 2th and  3th  column the patient's age and 
sex are recorded. In the 4th column the three therapy stages are set, while in the 5th 
column the medical records are reported based on clinically used response criteria 
for therapy response evaluation. The medical records characterize the progression of 
the disease between studies I and II (Early), studies II and III (Late) and studies I 
and III (Final). The patients condition is characterized as Partial Remission (PR) if 
the patient improves after treatment, as Stable Disease (SD) if the patient’s 
condition is stable, as Progressive Disease (PD) if the patient deteriorates and as 
Mixed Response (MR) in case of inability to evaluate properly patient’s condition. 
The 6th column records the fractal dimension characteristic of the particular study.  In 
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the 7th column the normalized integral difference of the muItifractal spectrum, 
Average Multifractal Index DMF , between studies I and II (Early), II and III (Late)  
and  I and III (Final) is reported. Formula 4.1 is used for the calculation of DMF 
between the early and the late stage, and similarly between the late and final stages, 
 
𝐷!" !!,! = 12𝐿 + 1 𝐷! 𝐼𝐼 − 𝐷! 𝐼!!!!!               4.1  
where L (-L) is the highest (lowest) order of index q.  In the last column the patient is 
characterized as Standard/Typical (Typ) if he/she only suffers from metastatic 
melanoma and the comparison of the analysis results and the medical records follow 
the typical pattern as explained in section 4.1. The patient is characterized as Non-
Typical (non-Typ) if he/she has a non-tumor related lesion or if he/she displays a 
non-standard mechanism of tracer spreading which makes the connection between 
the analysis and the medical records inconsistent. Patients characterized as non-Typ 
are individually discussed in the next section, 4.2. 
 
 
4.2 Unspecific tracer uptake not related to melanoma disease 
In this section we present two cases of non-typical patients, both of which show pre-
existing medical findings, not directly related to the melanoma disease. In both cases 
there is an uptake of FDG in non-tumorous areas and thus the results of the 
fractal/multifractal analysis are incompatible with the medical records. 
4.2.1 The case of colitis 
Patient P15 who suffers from metastatic melanoma presents one metastatic lesion in 
the 6th thoracic vertebra, which is clearly delineated in the maximum intensity 
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projection images in both follow-up studies (see Fig. 4.5). The same patient suffers 
also from fast evolving colitis, which is a side-effect of ipilimumab therapy and this is 
evident from the high uptake of FDG in the colon as appeared on Study-III. 
Furthermore, there is tracer retention in both ureters in the third study, which is also a 
finding not-related to the melanoma disease. Thus the distribution of FDG is divided 
between healthy organs, metastatic lesions and the colon area. This introduces a 
large error in the calculations and as a result the fractal dimensions increase in the 
Study II and decrease in the Study III, while the patient's  condition remains 
practically steady. 
 
4.2.2 The case of unspecific FDG uptake (thrombophlebitis) 
Patient P31 in the stage of treatment (Study-II) presents an increase in FDG uptake 
in the left leg which disappears in the Study-III. This uptake is not related to fast 
progressing melanoma but to an inflammatory vessel disease (see Fig. 4.6).  Due to 
this higher dispersion of the FDG biomarker the fractal dimension decreases in 
Study-II, as if the patient was deteriorating (developing further lesions) while the 
medical records indicate that the patient's condition is stable. Similar, hypermetabolic 
lesions not directly related to melanoma (unspecific findings) altering the results of 
the fractal/multifractal analysis are met in 7 out of 31 patients. 
The results of this section demonstrate that the fractal/multifractal analysis predicts 
correctly the evolution of metastatic melanoma in 83.3% (20 in 24) of the cases, 
giving results compatible with the medical records. In 7 cases, combined effect of 
melanoma and other non-specific findings (e.g. inflammatory lesions) gives results 
non-compatible with medical records. We stress again that the fractal/multifractal 
analysis of the metastatic melanoma spreading must be always complemented with 
medical assessment in order to exclude regions with false positive FDG uptake not 
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related to the disease. 
 
5. DISCUSSION 
In this section we first present the main results produced by a Kinetic Monte Carlo 
(KMC) model which mimics the transportation of malignant cells in the body. The 
model assumes biologically motivated processes such as diffusion of malignant cells 
through the blood (fractal) circulatory system and aggregation/colonization in the 
form of metastases at first contact of the diffusing cells with the surrounding healthy 
tissue. The results of this model are compared with the results of the PET/CT fractal 
analysis in section 5.2 while the limitations of this method and algorithms are 
discussed in 5.3. 
5.1 Kinetic Monte Carlo simulations and results 
Previous attempts to model the growth of tumours include both continuous and 
discrete approaches; for a review see ref. [13]. Most of these models deal with the 
growth of a single lesion as a result of the increase of the number of malignant cells 
locally. The propagation of tumour cells causing metastases has been studied using 
mainly continuous diffusion models [14],[15],[16].  In the current study we employ a 
stochastic microscopic approach [18],[19],[20], which allows the malignant cells to 
move randomly through the blood circulatory system. To model the metastasis 
process of melanoma we allow a small number of malignant cells to diffuse through 
the blood circulatory system and to cause occasional metastases in the adjacent 
healthy tissue or organs. The details of the kinetic Monte Carlo Algorithm and the 
spatial properties (fractal dimensions) of the distribution of the metastases are 
presented in detail in the Appendix. The main results of the KMC model is that as the 
malignant cells diffuse through the blood network colonizing at first contact (with 
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given, small probability), the colonies at the beginning of the process seem to be 
scattered randomly in the body. As time evolves, and more and more metastases 
occur, the metastatic topology will develop following the shape of the 
accommodating blood circulatory (or other hosting) network.  This is clearly shown in 
the time evolution of the fractal dimensions, which as time evolves approach the 
limiting set with df=2.7, characteristic of biological networks (see Appendix). The 
number of metastases in the KMC model is shown to follow a mixed mathematical 
increasing expression containing both exponential and power law parts, 
characteristic of fractal growth phenomena [17]. This mathematical formula can be 
used as predictor for the extension of the “volume'' of the metastatic lesions with 
time, provided that more frequent scannings of the patients are available in order to 
have enough data to accurately fix the values of the constants A, α and β in formula 
A.1. 
5.2 Fractal and multifractal properties of the PET/CT images 
We have used the methods of fractal and multifractal analysis to quantify the spatial 
extension of the malignant lesions in patients with metastatic melanoma, before and 
after treatment with ipilimumab. We analysed the PET/CT data from 31 patients at 
various stages of the disease. The fractal dimensions show low, decreasing values 
in patients with progressive disease, demonstrating the tendency of the tracer to 
concentrate in the sub-region of the body where metabolic activity takes place. 
However, in cases of successful medical treatment the lesions cease to attract the 
tracer and the fractal dimensions increase, showing the tendency of the tracer to 
diffuse in all parts of the body. In 20 out of 24 cases (83.3%) the results of the fractal 
and multifractal analysis were consistent with the medical records. For the remaining 
7 patients non-tumour related medical conditions led to abnormal tracer uptake, 
which gave false quantitative results. Two of these cases were demonstrated in 
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detail in sect. 4.2 as common atypical cases. 
To understand the quantitative results we have devised a stochastic kinetic model, 
based on the random drift of malignant cells through the blood circulatory system, 
which colonise randomly the surrounding tissue. The KMC model produces spatial 
distribution of metastases statistically similar to the ones observed in melanoma 
patients. 
5.3 Open Problem and Limitations 
One limitation of the present study is the selectivity of the algorithm used for the 
calculation of the fractal and multifractal dimensions. An important improvement to 
the algorithm would be the ability to exclude healthy organs where the tracer 
physiologically accumulates, as well as areas which show an unspecific non-tumour 
related FDG uptake. This became evident during the data evaluation and after the 
comparison between the results of the fractal analysis and the medical records. This 
problem requires the development of new, smart algorithms, able to mask areas with 
non-tumour related tracer uptake. 
 Other nonlinear measures such as the spatial correlations, higher order moments of 
the spatial distribution and clustering coefficients can be used to characterise the 
metastatic potential of the tumours and can improve the predictions of therapy 
outcome. These measures can be easily incorporated in the existing algorithms. 
6. CONCLUSIONS 
In this study we present a new method based on the calculations of fractal and 
multifractal dimensions of PET/CT images with FDG for monitoring of the therapeutic 
effect of ipilimumab in patients with metastatic melanoma. The results show enough 
evidence that the fractal and multifractal analysis have the potential to serve as 
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biomarkers, for therapy monitoring and for following the evolution of metastases in 
the body. This is a robust, operator independent method which is based on static 
images, can be easily implemented and demonstrated a correct classification rate of 
83.3% in this study. It can be used as an additional quantitative parameter for the 
assessment of the therapeutic outcome in clinical routine. Additional studies over a 
larger number of patients are needed to verify the impact of this method, as well as 
refinement of the developed algorithms to improve their predictive value. 
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APPENDIX: KINETIC MONTE CARLO MODELING 
According to earlier studies, the blood circulatory system has a branching structure 
whose geometry is fractal [3],[6]. As recapitulated in the Introduction, the fractal 
dimensions recorded in the literature is of the order of 2.6 - 2.7.  For this study, the 
blood circulatory network was constructed as a deterministic fractal embedded in 3D 
space representing the human body. The system (body) size was L x L x L= 81 x 81 
x 81 sites (3D representation) and the deterministic fractal network corresponding to 
the circulatory system was constructed iteratively within this 3D space. The fractal   
network spans the body and its fractal dimension df was chosen df
c = ln(18) /l n(3) = 
2.69 to be similar to the value reported in the literature. Once the positions of the 
sites belonging to the circulatory system are assigned, a small number (n=10) of 
malignant cells are released to diffuse [18],[21]. Their motion is restricted only within 
the areas covered by the circulatory network, i.e. they do not enter the areas outside 
the circulatory system, but occasionally, with very small probability (p) they infect the 
tissue (or organs) adjacent to the circulatory system.  As time passes, the number of 
tumor lesions increases and they span more and more areas around the body, all of 
them adjacent to the circulatory system. 
 To find the characteristics of the spatial distribution of the metastatic lesions 
produced by the KMC model, we use the same algorithm (box counting method) as in 
the study of the PET/CT images, i.e. we divide the  81 x 81 x 81 sites in cubic boxes 
of size s = 1,2, .... 20, and we calculate the number of boxes N(s) which contain at 
least one infected site. In a double logarithmic scale, the tangent of the number of 
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boxes N(s) versus the box size s expresses the fractal dimensions df(sim). The 
results of a typical simulation are shown in Fig. A.1. In this simulation each malignant 
cell diffuses for time T=100 x L3 where L is the linear size of the body (in voxels). At 
every elementary time step they diffuse randomly into nearest neighbouring sites 
(provided that they belong to the circulatory system) and with probability p=0.001 
they cause metastases in the nearby tissues or organs. 
 The number of infected regions at this time shows a typical power law with 
exponent df(sim)=2.76, close to the one of the circulatory system. In earlier times 
the metastases distribution is more sparse and the evolution of the fractal dimension 
with time is shown on Fig. A.2. This figure shows that as time increases the fractal 
dimension of the metastatic lesions approaches closely the one of the circulatory 
system. In fact, it tends to be a little higher. This is explained because the lesions are 
located all around the blood network covering a larger area than the network itself. 
Consequently, the corresponding fractal dimension tends to be relatively higher, in 
the limit of large times. We believe that the recorded PET/CT scans represent earlier, 
transient times before the malignant cells have the time to infect all the maximum 
body “volume” around the circulatory system. 
 Fractal laws have been also demonstrated in the time activity curve of FDG in 
different tumours [27]. A similar tendency is demonstrated by the number of lesions 
(metastases) Nm as a function of time shown in Fig. A.3. Nm increases at the 
beginning while after the transient it approaches a constant value, since most 
regions around the circulatory system have been infected and secondary infection of 
the same site is not allowed in the simulations. In the same figure the simulation 
results are approximated using a nonlinear curve fit of the type [21]: 
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𝑁!(𝑡) = 𝐴𝑡!exp(−𝛽𝑡)(𝐴. 1) 
 This formula takes into account the power law (fractal) nature of the problem, 
expressed by the exponent α and the leveling up of the curve which is attained by 
the exponential decay term exp(-βt). The nonlinear curve fit gives parameter values 
α= 0.808 and β= -0.0045, with correlation coefficient 0.999697. 
The minimal KMC model is a mechanistic scheme for the spreading of metastases in 
the human body. It accounts for the fractal spreading as calculated from the PET/CT 
images and has a similar fractal dimension. This model needs to be further explored 
in order to account for more precise metastasis characteristics. A first improvement 
would be to choose a spatial extension similar to the one used in PET/CT (eg. 400 x 
400 x 400 depending on the patient height) rather than the simple cubic (81 x 81 x 
81) used here. Instead of using a deterministic fractal we could mimic the circulatory 
network itself, drawing from medical images. We can also vary the number of 
malignant cells which circulate in the blood vessels and make their motion more 
realistic, rather than classical diffusion. It is also possible to arrange the malignant 
cells to start from a single tumorous area (e.g. the primary tumour) rather than 
spreading them randomly in the circulatory network. These additions to the KMC 
model could lead to even closer predictions of the spatial distribution of the lesions in 
metastatic melanoma.   
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Tables: 
Table 1: General features of PET images 
Specifications of PET Images 
Image size: 
Pixel size: 
Slice Thickness: 
Photometric Interpretation: 
File Type: 
400 x 400 pixels 
2.03642 x 2.03642 mm2 
4 mm 
MONOCHROME2 
.dcm (DICOM) 
 
Table 2:  Analysis Results for all Patients. 
Patient 
no. 
Age 
(years) 
SEX 
(M/F) 
Study Treatment 
Response 
Fractal 
Dimension 
Average 
Multifractal 
Index 
 Matching 
Results 
 
P1 
 
67 
 
M 
Early * 2.487 -0.064  
Late * 2.509 -0.030 Typ 
Final PR 2.525 -0.095  
        
 
P2 
 
48 
 
F 
Early PD(slow) 2.611 +0.043  
Late MR 2.588 -0.029 Typ 
Final MR 2.623 +0.013  
        
 
P3 
 
56 
 
M 
Early * 2.465 -0.119  
Late * 2.644 -0.015 Typ 
Final PR 2.643 -0.135  
        
   Early PD 2.688 -0.108  
P4 62 M Late MR 2.743 +0.003 Typ 
   Final PD 2.726 -0.104  
        
   Early PD (slow) 2.512 +0.181  
P5 37 F Late PD (slow) 2.395 -0.308 Typ 
   Final PD (slow) 2.602 -0.127  
        
   Early PD 2.634 -0.024  
P6 55 M Late PD 2.673 +0.174 Typ 
   Final PD 2.511 +0.150  
        
   Early PD 2.65 +0.077  
P7 55 M Late SD 2.629 -0.024 Typ 
   Final PD 2.624 +0.053  
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(Table 2 continued) 
 
Patient 
no. 
Age 
(years) 
SEX 
(M/F) 
Stage Treatment 
Response 
Fractal 
Dimension 
Average 
Multifractal 
Index 
 Matching 
Results 
 
P8 
 
74 
 
M 
Early PD(slow) 2.622 +0.01  
Late SD 2.629 +0.11 Typ 
Final PD 2.529 +0.13  
        
 
P9 
 
60 
 
F 
Early PD 2.618 +0.016  
Late PD 2.603 -0.14 Non-Typ 
Final PD 2.655  -0.124  
        
 
P10 
 
67 
 
M 
 
Early SD 2.589 -0.065  
Late PD 2.633 -0.044 Non-Typ 
Final PD 2.652 -0.11  
        
   Early MR 2.453 -0.369  
P11 56 M Late PD(slow) 2.719 +0.455 Typ 
   Final MR 2.4 +0.085  
        
   Early PD(slow) 2.637 +0.044  
P12 55 M Late PD 2.591 +0.03 Typ 
   Final PD 2.56 +0.075  
        
   Early SD 2.653 -0.113  
P13 71 M Late SD 2.676 +0.07 Typ 
   Final PR 2.683 -0.043  
        
   Early PD 2.616 +0.053  
P14 36 M Late PD 2.613 +0.106 Typ 
   Final PD 2.523 +0.159  
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(Table 2 continued) 
Patient 
no. 
Age 
(years) 
SEX 
(M/F) 
Stage Treatment 
Response 
Fractal 
Dimension 
Average 
Multifractal 
Index 
 Matching 
Results 
 
P15 
 
55 
 
M 
Early SD 2.593 -0.264  
Late SD 2.707 +0.281 Non-Typ 
Final SD 2.575 0.017  
        
 
P16 
 
73 
 
M 
Early SD 2.61 -0.075  
Late PD(slow) 2.676 +0.063 Typ 
Final PD(slow) 2.618 -0.012  
        
 
P17 
 
61 
 
F 
Early PD(slow) 2.698 +0.001  
Late PR 2.697 -0.033 Typ 
Final PR 2.705 -0.031  
        
   Early PD 2.697 -0.031  
P18 71 M Late PD 2.684 -0.047 Non-Typ 
   Final PD 2.713 -0.078  
        
   Early PD(slow) 2.611 -0.036  
P19 39 M Late SD 2.629 +0.088 Typ 
   Final PD(slow) 2.572 +0.052  
        
   Early PD 2.663 +0.045  
P20 70 M Late PD 2.659 -0.021 Typ 
   Final PD 2.621 +0.024  
        
   Early MR 2.533 +0.012  
P21 49 M Late PD 2.518 -0.036 Non-Typ 
   Final PD 2.556 -0.023  
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(Table 2 continued) 
Patient 
no. 
Age 
(years) 
SEX 
(M/F) 
Stage Treatment 
Response 
Fractal 
Dimension 
Average 
Multifractal 
Index 
 Matching 
Results 
 
P22 
 
66 
 
M 
Early SD 2.572 -0.037  
Late SD 2.561 +0.031 Typ 
Final SD 2.582 -0.005  
        
 
P23 
 
75 
 
M 
Early PR 2.68 +0.09  
Late PD 2.609 +0.011 Non-Typ 
Final PD 2.651 +0.101  
        
 
P24 
 
67 
 
M 
 
Early SD 2.687 +0.03  
Late PD(slow) 2.67 -0.071 Non-Typ 
Final PD(slow) 2.741 -0.04  
        
   Early MR 2.48 -0.319  
P25 65 F Late MR 2.699 +0.151 Typ 
   Final MR 2.614 -0.168  
        
   Early PR 2.65 -0.081  
P26 73 F Late PD 2.708 -0.07 Non-Typ 
   Final PD 2.714 -0.151  
        
   Early PD 2.602 +0.021  
P27 62 M Late PR 2.599 +0.047 Non-Typ 
   Final PR 2.576 +0.069  
        
   Early PR 2.699 +0.129  
P28 54 F Late PR 2.655 -0.187 Typ 
   Final PR 2.716 -0.058  
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(Table 2 continued) 
 
Patient 
no. 
Age 
(years) 
SEX 
(M/F) 
Stage Treatment 
Response 
Fractal 
Dimension 
Average 
Multifractal 
Index 
 Matching 
Results 
 
P29 
 
61 
 
F 
 
Early PR 2.622 -0.019  
Late PR 2.632 -0.032 Non-Typ 
Final PR 2.651 -0.052  
        
 
P30 
 
53 
 
M 
Early SD 2.544 +0.051  
Late SD 2.534 -0.203 Typ 
Final SD 2.676 -0.152  
        
 
P31 
 
78 
 
F 
Early SD 2.588 +0.046  
Late SD 2.554 -0.165 Non-Typ 
Final SD 2.633 -0.118  
        
Healthy 
Subject 
73 M - - 2.723 - - 
 
       *no medical records 
            PR - Partial Remission, SD - Stable Disease, PD - Progressive Disease, MR - Mixed Response 
Early Stage :Study-I → Study-II, Late Stage:Study-II → Study-III, Final Stage:Study-I →Study-III 
Typ - correspondence between analysis results and medical records, non-Typ - no correspondence 
between analysis results and medical records 
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Figure Legends: 
Fig. 4.1. The number of boxes N(s) as a function of the box size s for patient P3. His 
condition improves after medical treatment with ipilimumab.	
Fig. 4.2.The generalized dimensions Dq as a function of the index q for patient P3. 
The patient's condition improves after medical treatment with ipilimumab.	
Fig. 4.3. The number of boxes N(s) as a function of the box size s for patient P12. 
His condition deteriorates during medical treatment with ipilimumab. 
Fig. 4.4. The generalized dimensions Dq as a function of the index q for patient P12. 
The patient's condition deteriorates during medical treatment with ipilimumab. 
Fig.4.5. PET/CT images of patient P24 suffering from colitis. The patient presents 
high uptake of the FDG biomarker not only due to the melanoma metastases visible 
in his/her left leg but also due to the presence of colitis, not related to the melanoma. 
Fig. 4.6. PET/CT images of patient P31 at the three stages. The patient presents 
high unusual uptake of the FDG biomarker in his/her left leg at the 2nd stage of 
treatment, not related to the melanoma. 
Fig. A.1. The number of boxes containing metastases as a function of the box size s. 
The linear system size is L=81, the probability of infection is p=0.001, the infecting 
seeds are n=10 and the time of the simulation is T=100 x L3. 
Fig. A.2. The temporal evolution of df(sim). 
Fig. A.3. Evolution of the metastatic lesions with time. The crosses represent the 
simulation results and the red dashed line the nonlinear curve fit. 
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Fig. 4.2. 
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Fig. 4.3. 
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Fig. 4.4.  
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Fig. 4.5. 
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Fig. 4.6.  
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Fig. A.1.  
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Fig. A.2.  
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